Madrigal Pharmaceuticals (MDGL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MDGL Madrigal Pharmaceuticals

Watchlist

328.180
+11.090+3.50%

Trading Nov 21 15:40 ET

7.16BMarket Cap-13111P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra
Seeking AlphaNov 20 14:02 ET
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Moomoo NewsNov 20 13:31 ET · Ratings
Madrigal Pharmaceuticals Price Target Raised to $400 From $350 at Oppenheimer
TipRanksNov 20 13:06 ET
Trump Media Saw the Largest Increase in Short Interest in October
Seeking AlphaNov 20 10:57 ET
Express News | Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
BenzingaNov 20 08:46 ET
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Moomoo NewsNov 19 07:31 ET · Ratings

Comments

Stock_Drift

Nov 1 10:33

Unusual Volume Ticks. 11:32am

$Madrigal Pharmaceuticals (MDGL.US)$ $Nuburu (BURU.US)$ $Pro-Dex (PDEX.US)$ $ASP Isotopes (ASPI.US)$ $GRI Bio (GRI.US)$ $Vast Renewables (VSTE.US)$ $MicroCloud Hologram (HOLO.US)$ $Theriva Biologics (TOVX.US)$ $Pluribus Technologies Corp (PLRB.CA)$ $Ensysce Biosciences (ENSC.US)$ $Athira (ATHA.US)$ $Globalstar (GSAT.US)$ $ChromaDex (CDXC.US)$
📊⚡️📊

Jerry Kronenberg

Jun 11 14:52

Columns Madrigal Pharmaceuticals Rallies 15% on Wolfe Research 'Outperform' Rating

$Madrigal Pharmaceuticals (MDGL.US)$ rose some 15% Tuesday after Wolfe Research reportedly initiated coverage of the pharma firm with a "Outperform" rating.
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...